Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Melanoma 1HIV Infections 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 8Vincristine 7Etoposide 7Cyclophosphamide 7Rituximab 5Prednisone 5Filgrastim 5Zidovudine 3Bleomycin 3Vinblastine 2Thalidomide 2Paclitaxel 2Mitoxantrone 2Interferon-alpha 2Interferon alpha-2 2Dacarbazine 2Cytarabine 2Cisplatin 2ziconotide 1vesnarinone 1tin etiopurpurin 1nirogacestat 1liposomal doxorubicin 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1efavirenz 1dehydroftorafur 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HIV Infections × Remote Patient Monitoring × Clear all
NCT03834571 2022-06-21

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

AIDS Malignancy Consortium

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡